TAK Articles, Takeda Pharmaceutical Company Limited American Depositary Shares - From 05/13/24

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease Ta...

On Thursday, Japan’s drugmaker Takeda Pharmaceutical Company Limited (NYSE:TAK) announced a restructuring after the company re...

Neurocrine Biosciences Inc (NASDAQ:NBIX) revealed on Tuesday topline data for its Phase 2 SAVITRI study of NBI-1065845 in adult subjects with maj...

Monday, the FDA approved Takeda Pharmaceutical Co Ltd’s (NYSE:TAK) Eohilia (budesonide oral suspension), the first and only FDA-app...

Thursday after close, Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results from a Phase 2b trial evaluating TAK-861, an oral ...

Thursday, Takeda Pharmaceutical Co Ltd (NYSE:TAK) reported a third-quarter 2023 core net profit of ¥235.9 billion, down 9.4% and&nb...

Just as large pharma companies prepare a showdown with Medicare's newfound power to negotiate down drug prices, several major drug companies ar...

Availability of GLASSIA® represents significant milestone for patients with emphysema due to severe hereditary deficiency of Alpha-1 antitryp...

Monday, Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered into a license agreement with Otsuka Pharmaceutical Co Ltd under which...

Thursday, Neurocrine Biosciences Inc (NASDAQ: NBIX) released Phase 2 study results from two signal-seeking pipeline programs in...